VYNE Biotech Post Earnings

NASDAQ:VYNE   VYNE Therapeutics Inc.
VYNE had a favorable earnings report last week. Fundamentally, analysts predict ( linked)

approximately a doubling of the shart price in the next year. Like many low share priced

biotechnology stocks the price is based on perceived future earnings which can be affected

by favorable FDA process, or well-received research at industry conferences and changing

financials within the company. In general, they have a low beta meaning these stocks are not

general market responsive and run on their own present or future merits.

On the 15-minute chart VYNE was trending down into earnings and the pivoted with a reversal

into the present. The Luxalgo AI "Echo indicator" predicts an upside of 20% in the next two

days before a consolidation period. The "Trendflex" indicator has flipped to postiive and green.

I will take this long trade with a stop loss of $0.15 per share and target of $9.00 over two days

for a 20% ROI and a R:R of 0.15 risk / $ 1.50 reward for a 10:1> Iwill only take biotechology

trades long with a high R:R due to the inheret risk level.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.